抗脂综合征中的天然补充剂:需要进一步研究的案例
1Northwell Health, Division of Rheumatology, Donald and Barbara Zucker School of Medicine, Great Neck, NY, United States of America.
Clinical immunology (Orlando, Fla.)
|November 30, 2023
概括
天然补充剂在治疗自身免疫性疾病抗脂综合征 (APS) 方面表现有前途. 研究探讨了维生素D,欧米茄-3和其他人在APS治疗中的抗氧化和抗炎作用.
科学领域:
- 自免疫性疾病 自免疫性疾病
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗脂综合征 (APS) 涉及由于抗脂抗体 (aPL) 的血液凝块和怀孕问题.
- 目前的标准治疗 (华法林) 有局限性,因此需要更安全的治疗方法.
- APS的发病包括氧化应激和炎症途径.
研究的目的:
- 审查APS天然补充剂的证据.
- 专注于维生素D,欧米茄-3脂肪酸,辅酶Q10,生醇和异甲.
- 评估它们作为APS中血栓预防或辅助的潜力.
主要方法:
- 机械学,流行病学和临床研究的系统审查.
- 对针对APS通路的自然化合物的分析.
- 在文献中搜索有关特定补充剂的证据.
主要成果:
- 自然补充剂具有与APS相关的抗血栓,抗炎和抗氧化特性.
- 初步证据表明,维生素D,omega-3s,CoQ10,生醇和isoquercetin的潜在益处.
- 机制与APS病理生理学一致,包括氧化应激减轻.
结论:
- 天然补充剂需要进一步调查APS管理.
- 新型治疗策略的潜力超出标准抗凝药.
- 需要未来的临床试验来确定疗效和安全性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188


